ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0881

Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica

Patricia Harkins1, Sharon Cowley2, Robert Harrington3, David Kane4, Jean Dunne5, Niall conlon6 and Richard Conway7, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3St. James's Hospital, Dublin, Dublin, Ireland, 4Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 5Trinity College Dublin, Dublin, 6Trinity Colleg Dublin, Dublin, 7Trinity College Dublin, Dublin, Ireland

Meeting: ACR Convergence 2024

Keywords: cytokines, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Despite polymyalgia rheumatica (PMR) being the most common inflammatory rheumatic disease in those over the age of 50 years, there remains a significant unmet need for a reliable serum biomarker of disease activity, to aid the diagnosis, and the identification of disease relapse. The aim of this pilot study was to evaluate the levels of 7 serum cytokines in a cohort of newly diagnosed PMR patients.

Methods: 15 consecutive patients, who had active, untreated PMR were recruited from a fast track PMR clinic. Those with signs, symptoms or imaging confirmation of GCA were excluded. The following circulating cytokines were then measured using ELISA on participants serum: MCP-1(CCL2) , interleukin-6 (IL-6), CXCL9 (MIG), MIP-1 alpha (CCL3), Tumour necrosis factor alpha (TNF-a), interleukin-1 beta (IL-1b) and interleukin-17A (IL-17A). The statistical analysis was performed using STATA MP Version 18.

Results: A total of 15 patients with PMR were studied (33% female; 67% male). The mean age was 71.71 (SD 5.97). In reference to defined manufacturer parameters, at diagnosis serum MCP-1 levels were elevated in 14/15 (93%), with a median level of 732.5pg/ml (571, 921). Serum IL-6 levels were elevated in 10/15 (67%) with a median level of 11.85 pg/ml (6.05, 31.8). CXCL9 was elevated in 14/14 (100%), with a median level of 2184pg/ml (1180, 3897.5). Levels of MIP-1 alpha were elevated in 4/14 (28.6%) patients, with a median level of 91.1 pg/ml (76.5, 105). IL-1b was elevated in 2/15 (13.3%) with a median level of 0.445pg/ml (0.27, 0.815). TNF-a was elevated in 1/15 (6.7%) with a median level of 15.35pg/ml (12.85, 16.8). Finally, IL-17A was only available in 6 patients, with 5/6 (83%) demonstrating increased levels, with a median IL-17A level of 3.02 (2.89,3.27).

Conclusion: Our pilot study has demonstrated the potential utility of serum CXCL-9, MCP-1 and IL-17A in the diagnosis of those with isolated PMR. Our study offers the advantage of inclusion of an isolated PMR cohort, who are naïve to any treatment including steroid. Our findings provide promise for future large scale prospective studies exploring the role of these cytokines in PMR, which may also facilitate a deeper understanding of the inflammatory and immune mechanisms underlying PMR pathophysiology.


Disclosures: P. Harkins: Janssen Pharmaceuticals, 5, Novartis Pharmaceuticals, 5; S. Cowley: AbbVie/Abbott, 12, Support to attend conference, Novartis, 5, 12, Support to attend conference; R. Harrington: None; D. Kane: None; J. Dunne: None; N. conlon: None; R. Conway: AbbVie/Abbott, 5, 6, Celltrion, 5, Fresenius Kabi, 6, Galapagos, 6, Janssen, 5, 6, Novartis, 5, 6, UCB, 6, Viatris, 6.

To cite this abstract in AMA style:

Harkins P, Cowley S, Harrington R, Kane D, Dunne J, conlon N, Conway R. Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cytokine-profile-of-newly-diagnosed-patients-with-isolated-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cytokine-profile-of-newly-diagnosed-patients-with-isolated-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology